NEW YORK, NY / ACCESSWIRE / September 11, 2017 / U.S. markets, the dollar and bond yields posted weekly losses on the combination of weather concerns and rising geopolitical tensions between the U.S. and North Korea. The Dow Jones Industrial Average gained 0.06 percent to close at 21,797.79, down 189.77 for the week, while the S&P 500 Index fell 0.15 percent to close at 2,461.43, down 0.61 percent for the week.

"Today is sort of a hunker-down sort of day," said Kate Warne, investment strategist at Edward Jones. "After insurance stocks dropped sharply earlier in the week, investors are seeing them as an opportunity and hoping Irma isn't as bad as feared." "We'll see stocks hover around flatline," Warn added.

RDI Initiates Coverage on:

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) - https://rdinvesting.com/news/?ticker=ACAD

Clovis Oncology Inc. (NASDAQ: CLVS) - https://rdinvesting.com/news/?ticker=CLVS

ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) stock moved 3.16% higher Friday, to close the day at $36.93. The stock recorded a trading volume of 2,276,950 shares, which was above its three months average volume of 1,468,160 shares. In the last year, ACADIA Pharmaceuticals Inc.'s shares have traded in a range of 20.68 - 40.83. The share price has gained 78.58% from its 52-week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $31.97 is greater than its 200-day moving average of $31.68. Shares of ACADIA Pharmaceuticals have gained approximately 28.05 percent year-to-date.

Access RDI's ACADIA Pharmaceuticals Inc. Research Report at: https://rdinvesting.com/news/?ticker=ACAD

On Friday, shares in Clovis Oncology Inc. (NASDAQ: CLVS) recorded a trading volume of 3,076,918 shares, which was above the three months average volume of 1,943,900 shares. The stock ended the day 7.12% lower at 67.17. The share price has gained 163.41% from its 52-week low with a 52-week trading range of 25.50 - 99.45.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $76.78 is greater than its 200-day moving average of $68.43. Shares of Clovis Oncology have gained approximately 51.22 percent year-to-date.

Access RDI's Clovis Oncology Inc. Research Report at: https://rdinvesting.com/news/?ticker=CLVS

Our Actionable Research on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Clovis Oncology Inc. (NASDAQ: CLVS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer:

This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com